{
    "Trade/Device Name(s)": [
        "ONLINE DAT Benzodiazepines II"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K221765",
    "Predicate Device Reference 510(k) Number(s)": [
        "K043327"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JXM"
    ],
    "Summary Letter Date": "December 23, 2022",
    "Summary Letter Received Date": "June 17, 2022",
    "Submission Date": "June 6, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.3170"
    ],
    "Regulation Name(s)": [
        "Benzodiazepine test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Benzodiazepines",
        "Nordiazepam",
        "Alprazolam",
        "Diazepam",
        "Lorazepam",
        "Lorazepam glucuronide",
        "Oxazepam",
        "Oxazepam glucuronide",
        "Temazepam",
        "Temazepam glucuronide",
        "3-Hydroxybromazepam",
        "3-Hydroxyflubromazepam",
        "3-Hydroxyflunitrazepam",
        "4-Hydroxyalprazolam",
        "4-Hydroxytriazolam",
        "7-Acetamidonitrazepam",
        "7-Aminoclonazepam",
        "7-Aminoflunitrazepam",
        "7-Aminonimetazepam",
        "7-Aminonitrazepam",
        "Bentazepam",
        "Bromazepam",
        "Brotiazolam",
        "Chlordiazepoxide",
        "Clobazam",
        "Clonazepam",
        "Clonazolam",
        "Clorazepate",
        "Delorazepam",
        "Demoxepam",
        "Desalkylflurazepam",
        "Deschloretizolam",
        "Desmethylchlordiazepoxide",
        "Desmethylflunitrazepam",
        "Desmethylmedazepam",
        "Diclazepam",
        "Didesethylflurazepam",
        "Estazolam",
        "Etizolam",
        "Flubromazepam",
        "Flubromazolam",
        "Flunitrazepam",
        "Flurazepam",
        "Halazepam",
        "Hydroxyethylflurazepam",
        "Lormetazepam",
        "Meclonazepam",
        "Medazepam",
        "Midazolam",
        "Nifoxipam",
        "Nimetazepam",
        "Nitrazepam",
        "Phenazepam",
        "Pinazepam",
        "Prazepam",
        "Pyrazolam",
        "Tetrazepam",
        "Triazolam",
        "\u03b1-Hydroxyalprazolam",
        "\u03b1-Hydroxyalprazolamglucuronide",
        "\u03b1-Hydroxymidazolam",
        "\u03b1-Hydroxymidazolamglucuronide",
        "\u03b1-Hydroxytriazolam"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "cobas c systems",
        "cobas c 501"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay (EIA)",
        "Kinetic interaction of microparticles in solution (KIMS)"
    ],
    "Methodologies": [
        "Qualitative detection",
        "Semi-quantitative detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Roche Diagnostics ONLINE DAT Benzodiazepines II enzyme immunoassay for detection of benzodiazepines in human urine using cobas c systems",
    "Indications for Use Summary": "In vitro diagnostic test for qualitative and semi-quantitative detection of benzodiazepines in human urine on cobas c systems at 100, 200, and 300 ng/mL cutoffs; results may be used for assay performance assessment and require confirmatory methods for definitive analytical results",
    "fda_folder": "Toxicology"
}